Ridgewood, New York Clinical Trials

A listing of Ridgewood, New York clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 405 clinical trials
Manhattan Vision Screening and Follow-Up Study

The investigators are conducting a 5-year prospective, cluster-randomized controlled trial, funded by the Centers for Disease Control (CDC), which provides vision screenings to underserved, vulnerable New York City residents living in affordable housing buildings in Harlem and Washington Heights.

vision screening
Columbia University
 (9.8 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
Families Children and Teachers Thriving Together

The current study examines the impact of ParentCorps in high-poverty district schools in New York City (NYC). The study is conducted within the context of the NYC Department of Education (DOE) Pre-K Thrive initiative. As part of this initiative, the Center for Early Childhood Health and Development (CEHD) at NYU …

inspire
cehd
NYU Langone Health
 (5.3 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
Study of Lademirsen (SAR339375) in Patients With Alport Syndrome

Primary Objectives: To assess the efficacy of lademirsen (SAR339375) in reducing the decline in renal function To assess the safety and tolerability of lademirsen (SAR339375) in subjects with Alport syndrome Secondary Objectives: To assess plasma pharmacokinetic (PK) parameters of the parent compound and its metabolites To assess the potential formation …

Columbia University Medical Center_Investigational Site Number :8400004
 (9.8 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +22 other locations
Study of Lademirsen (SAR339375) in Patients With Alport Syndrome  

Primary Objectives: To assess the efficacy of lademirsen (SAR339375) in reducing the decline in renal function To assess the safety and tolerability of lademirsen (SAR339375) in subjects with Alport syndrome Secondary Objectives: To assess plasma pharmacokinetic (PK) parameters of the parent compound and its metabolites To assess the potential formation …

Columbia University Medical Center_Investigational Site Number :8400004
 (9.8 away)
  • 0 views
  • 01 Dec, 2025
  • +19 other locations
UAT Study

Bowen Test Study Overview

Formal Site
 (2.8 away) Contact site
  • 0 views
  • 09 May, 2025
  • +7 other locations
None

Memorial Sloan Kettering Cancer Center
 (5.4 away) Contact site
  • 0 views
  • 19 May, 2025
  • +19 other locations
A Study to Evaluate the Efficacy and Safety of Frexalimab, SAR442970, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease (RESULT)

This is a parallel, Phase 2a, double-blind, 6-arm study for the treatment of primary focal segmental glomerulosclerosis (FSGS) or primary minimal change disease (MCD).The purpose of this study is to measure the change in proteinuria and its impact on the rates of remission of nephrotic syndrome with frexalimab, SAR442970, or …

Investigational Site Number : 8400001
 (9.8 away) Contact site
  • 0 views
  • 20 Jun, 2025
  • +24 other locations
A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)

A phase 3 double blind, placebo controlled study evaluating the efficacy and safety of AL001 in participants at risk for or with frontotemporal dementia due to heterozygous mutations in the progranulin gene.

aphasia
progranulin
pick's disease
dementia
Irving Institute for Clinical and Translational Research
 (9.8 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +46 other locations
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.

treatment regimen
lasmiditan
migraine
headache
ly573144
Care Access Research - Bronx
 (8.8 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +162 other locations
ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease  

The purpose of this study is to evaluate the safety and efficacy of the ExAblate Model 4000 Type 2.0 System as a tool to disrupt the blood-brain barrier (BBB) in patients with probable Alzheimer's Disease (AD).

alzheimer's disease
Weill Cornell Medicine
 (5.4 away)
  • 0 views
  • 09 May, 2025
  • +2 other locations